Aphton Announces Mutual Agreement to Dissolve Co-Promotion and Licensing Agreement Related to Anti-Cancer Product Insegia(TM)
Dissolution Allows for New Partnership Opportunities and Further Development of Insegia in Gastric Cancer
11-Nov-2005 -
Aphton Corporation announced that it has entered into a mutual decision and agreement to terminate the co-promotion and licensing agreement with sanofi pasteur related to Aphton's lead immunotherapy compound, Insegia(TM) (G17DT immunogen). The agreements related to the co-promotion, licensing and ...
clinical trials
diphtheria
gastric cancer
+2